Indication

Neuregulin 1 fusion-positive cholangiocarcinoma

Neuregulin 1 (NRG1) fusion-positive cholangiocarcinoma is an exceedingly rare, biologically distinct molecular subtype of bile duct adenocarcinoma affecting the intrahepatic or extrahepatic biliary tract. Read more about Neuregulin 1 fusion-positive cholangiocarcinoma

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Neuregulin 1 fusion-positive cholangiocarcinoma therapies.

Showing 1–1 of 1 drugs

Filter & compare in the drug finder →Opens the drug finder with Neuregulin 1 fusion-positive cholangiocarcinoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Neuregulin 1 fusion-positive cholangiocarcinoma.

Neuregulin 1 (NRG1) fusion-positive cholangiocarcinoma is an exceedingly rare, biologically distinct molecular subtype of bile duct adenocarcinoma affecting the intrahepatic or extrahepatic biliary tract.

The condition is characterized by chromosomal rearrangements that join the *NRG1* gene with various upstream fusion partners.

These chimeric transcripts generate aberrantly expressed chimeric NRG1 ligands that constitutively bind human epidermal growth factor receptor 3 (HER3), inducing dimerization with HER2 and triggering uncontrolled oncogenic signaling cascades, such as the MAPK and PI3K/Akt pathways.

Clinically, these tumors behave aggressively, often presenting at an advanced or metastatic stage and frequently arising in younger adults compared with typical cholangiocarcinoma populations.

Personalize your experience

Follow Neuregulin 1 fusion-positive cholangiocarcinoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it